Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.34 USD | -1.89% | +4.06% | +54.20% |
Financials (USD)
Sales 2024 * | 42.79M | Sales 2025 * | 114M | Capitalization | 1.95B |
---|---|---|---|---|---|
Net income 2024 * | -263M | Net income 2025 * | -345M | EV / Sales 2024 * | 43.8 x |
Net cash position 2024 * | 76.75M | Net cash position 2025 * | 15.43M | EV / Sales 2025 * | 17 x |
P/E ratio 2024 * |
-7.6
x | P/E ratio 2025 * |
-6.14
x | Employees | 385 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.65% |
Latest transcript on Agios Pharmaceuticals, Inc.
1 day | -1.89% | ||
1 week | +4.06% | ||
Current month | +5.66% | ||
1 month | +16.68% | ||
3 months | +29.54% | ||
6 months | +54.27% | ||
Current year | +54.20% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Goff
CEO | Chief Executive Officer | 55 | 22-08-07 |
Cecilia Jones
DFI | Director of Finance/CFO | 49 | 22-09-25 |
Jacqualyn Fouse
CHM | Chairman | 62 | 17-12-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeffrey Capello
BRD | Director/Board Member | 69 | 23-05-31 |
Director/Board Member | 64 | 14-12-08 | |
May Kin Ho
BRD | Director/Board Member | 71 | 15-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.52% | 1 M€ | +0.15% | - | |
0.16% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 34.34 | -1.89% | 654,883 |
24-05-16 | 35 | -0.51% | 360,179 |
24-05-15 | 35.18 | +3.05% | 524,742 |
24-05-14 | 34.14 | +1.79% | 518,105 |
24-05-13 | 33.54 | +1.64% | 560,367 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.20% | 1.95B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- AGIO Stock